Venous leg ulcers (VLUs) are the most severe complication caused by the progression of chronic venous insufficiency. They account for approximately 70–90% of all chronic leg ulcers (CLUs). A total of 1% of the Western population will suffer at some time in their lives from a VLU. Furthermore, most CLUs are VLUs, defined as chronic leg wounds that show no tendency to heal after three months of appropriate treatment or are still not fully healed at 12 months. The essential feature of VLUs is their recurrence.
1. Definition of Venous Leg Ulcer
According to the CEAP classification, revised in 2004, a venous leg ulcer (VLU) is defined as a full-thickness skin defect, most frequently in the lower leg and ankle region, that fails to heal spontaneously and is sustained by venous hypertension due to chronic venous disease
[1]. Venous leg ulcers (VLUs) usually occur at the malleolar part on the medial and lateral sides of the ankle. However, they also may appear on the supra-malleolar and infra-malleolar areas of the leg and foot
[2]. Furthermore, most VLUs are chronic leg ulcers (CLUs), defined as chronic leg wounds that show no tendency to heal after three months of appropriate treatment or are still not fully healed at 12 months
[3]. Moreover, it is estimated that between 40% and 50% remain active between 6 and 12 months, and that 10% remain active up to 5 years
[4]. It also has been shown that a VLU that fails to decrease in size by 30% (percentage area reduction) of its initial size over the first four weeks of treatment has a 68% probability of failing to heal within 24 weeks
[5].
2. Pathophysiology of Venous Ulcers
Patients with venous leg ulcers have venous hypertension and abnormally sustained venous pressure elevation upon ambulation (normal venous pressure decreases with walking), which results from vein reflux or outflow obstruction.
Venous outflow may also be impaired due to poor calf muscle pump function, which damages the venous system’s ability to overcome the venous blood return to the heart. The limitation of ankle movement seems to be an essential contributor to calf muscle pump failure and a risk factor for ulceration
[6]. Several risk factors of VLU development have been identified, including, among others, an age older than 55 years, an increased body mass index (BMI), a family history of CVI, a history of venous thromboembolism disease and superficial thrombophlebitis, a sedentary lifestyle, skeletal or joint disease of the legs, multiparous women, and severe stages of chronic venous diseases (lipodermatosclerosis, active or healed venous ulcers in history)
[7].
Although venous hypertension results in ulceration, the exact mechanism remains unclear. Several hypotheses have been proposed, such as abnormalities of the fibrinolytic system, peripapillary fibrin deposition causing decreased oxygen diffusion to tissues, the trapping of growth factors by extravasated macromolecules around the vessels and in the dermis, limiting their function, and leucocyte margination and activation with the subsequent local release of inflammatory mediators
[8]. Consequent microcirculatory changes lead to venous hypertensive microangiopathy (enlarged permeable capillaries, abnormally increased skin flux, edema, altered microlymphatic circulation, decreased partial pressure of oxygen, and increased carbon dioxide) that results in ulceration
[9].
The effect on the microcirculation begins with altered shear stress on the endothelial cells, causing them to release vasoactive agents and express selectins, inflammatory molecules, chemokines, and prothrombotic precursors
[10][11]. Mechanical forces and low shear stress are sensed by the endothelial cells via intercellular adhesion molecules-1 (ICAM1, CD 54), vascular cell adhesion molecules1 (VCAM-1, CD-106), and endothelial leucocyte adhesion molecule1 (CD-62, E-selectin). CVD patients have increased expressions of ICAM-1 and VCAM-1. A key component of inflammation in VLUs is the increased expressions of matrix metalloproteinases and the production of cytokines (Transforming growth factor-β1, Tumor necrosis factor-α, Interleukin-1)
[12].
Another area of research in the pathophysiology of LVUs is gap junctions. Gap junctions are proteins that play critical roles in the pathogenesis of chronic wounds, mainly involved in inflammation, edema, and fibrosis. Connexins (a component of gap junctions) are abnormally elevated in the wound margins of VLUs. Connexins seem to play an essential role in the inflammatory response and VLU healing
[13].
The pathophysiology of venous ulcers is shown in Figure 1.
Figure 1. Pathophysiology of venous ulcers.
3. Diagnosis of Venous Ulcers
The diagnosis of leg ulcers is based on medical history, clinical assessments, functional/diagnostics testing, blood tests, biopsy, bacteriologic or mycologic swabs, histopathology, and direct immunofluorescence
[14][15][16][17] (
Table 1). The clinical diagnosis as the first step is available everywhere, allowing for the diagnosis of the majority of VLUs. In the next step, several complementary diagnostic procedures are used
[12][14] (
Table 2).
Table 1. Diagnostics of leg ulcers.
Regarding investigations, individual studies’ recommendations could be more robust
[10][11] (
Table 3).
Table 3. Recommendations of investigations in patients with venous leg ulcers/level of evidence.